← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Mucommune, Llc
Morrisville, NC
$24,205,412
Total funding
31
Grants
Funding over time
peak $6.4M · FY2016–25$10M$7.5M$5M$2.5M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,205,412 · 31
By mechanism
R44$16,208,024 · 10
R43$4,809,734 · 16
R33$1,622,042 · 1
R61$986,704 · 2
N43$306,183 · 1
R41$272,725 · 1
Investigators at Mucommune, Llc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
SBIR: In vivo engineering of multifaceted B7H3.CAR-T cells for cellular immunotherapy of pancreatic ductal adenocarcinoma$1,146,618
R44 · FY2025 · CA
Fast Dissolving MM008 Tablet for Instant On-Demand Non-Hormonal Contraception$1,130,880
R44 · FY2025 · HD
INDâenabling development of MMâ008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring$1,039,122
R44 · FY2022 · HD
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV$1,037,049
R44 · FY2024 · AI
SBIR: In vivo validation and IND-enabling development of MM004, a bispecific inhaled immunotherapy for RSV and MPV$1,036,484
R44 · FY2023 · AI
SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy$1,031,566
R44 · FY2025 · CA
INDâenabling development of MMâ008 IVR, an antibody-based nonhormonal contraceptive intravaginal ring$1,028,445
R44 · FY2023 · HD
IND-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis$1,025,000
R44 · FY2025 · AI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV$999,032
R44 · FY2020 · AI
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV$995,652
R44 · FY2021 · AI
In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring$972,804
R44 · FY2020 · HD
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV$910,955
R44 · FY2021 · HD
Development of RespiraClear for targeted mucosal treatment of RSV infections$891,585
R44 · FY2022 · AI
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV$791,080
R44 · FY2022 · HD
In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ring$756,985
R44 · FY2021 · HD
Development of RespiraClear for targeted mucosal treatment of RSV infections$658,372
R44 · FY2021 · AI
Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructs$545,344
R33 · FY2021 · HD
Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructs$540,726
R33 · FY2022 · HD
Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructs$535,972
R33 · FY2023 · HD
Development of MM010, a PEG-specific intervention that blocks allergic response and restores effective repeat dosing of peg-asparaginase in patients with acute lymphoblastic leukemia$409,732
R43 · FY2025 · CA